Navigation Links
Elekta's New Line of Stereotactic Treatment Solutions is Redefining Excellence in Stereotaxy, a Case at a Time
Date:4/24/2008

ATLANTA and CHICAGO, April 24 /PRNewswire/ -- Elekta, a global leader in minimally invasive neurosurgery will feature its latest line of stereotactic solutions at the 76th Annual Meeting of the American Association of Neurological Surgeons' (AANS), April 26 - May 1 in Chicago, Illinois. Highlights include Leksell Gamma Knife(R) Perfexion(TM) and Elekta Axesse(TM), two stereotactic treatment solutions that are creating new possibilities for the most challenging cases.

Now in clinical use in twenty locations across North America, Leksell Gamma Knife Perfexion combines the proven precision of the revolutionary Leksell Gamma Knife, with a three hundred percent expansion in clinical reach to treat a wider range of targets faster and more efficiently than ever before. The system's unique geometric and dosimetric design simultaneously administers hundreds of beams of low-intensity radiation that converge to deliver a single, therapeutic dose of radiation with pin-point accuracy to the most difficult targets; while integrated treatment planning and delivery streamlines the radiosurgery process to treat even multiple brain lesions in a single automated procedure.

Fully optimized for neurosurgery, Elekta Axesse is ideally suited for stereotactic radiosurgery or radiotherapy of the spine and body, providing total treatment control with proven technology that minimizes time-on-table and maximizes treatment capacity. And with volumetric 3D imaging, six-degree patient positioning, and fine-resolution beam shaping of Elekta Axesse make it a versatile, crossover treatment solution for neuro-oncology.

"Elekta is committed to supporting the neurosurgeon by providing highly refined tools that support specific clinical objectives," says Joseph K. Jachinowski, President and CEO of Elekta North America. "Technology that is perfectly aligned to the physician and the case at hand naturally results in faster treatments, increased productivity, higher profitability, and most of all, more quality time for the patient."

In addition to its latest line of radiosurgery and radiotherapy solutions as well as cases studies highlighting their clinical use, Elekta will exhibit new accessories for the world's most widely used stereotactic product line, Leksell Stereotactic System(R), and Elekta Neuromag(R), the world's most advanced magnetoencephalography (MEG) system.

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state-of-the-art tools to fight serious disease.

Elekta provides advanced clinical solutions and comprehensive management and information systems, as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in more than 5,000 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) for stereotactic radiosurgery or radiotherapy of the spine and body and Elekta Synergy(R) for advanced intensity modulated and image guided radiation therapy, as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With more than 2,500 employees globally, Elekta corporate headquarters are located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb.


'/>"/>
SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):